We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
GERN (market cap is $0.263B was $0.186B)
Geron is a high-tech biotech developing treatments for various disorders based on manipulating telomeres, the molecules that help manage cell death. Cancer cells don’t die on time. Autoimmune disorders can be based on cells that die too soon. Manage the telomeres and potentially manage many disorders. Currently, Geron is targeting cancer treatments.
Welcome to the ‘but’ part of the description. Geron has been targeting cancers for decades. Twenty years ago they also held the patents for cloning, were developing stem cell therapies, and of course, telomeres. None of their treatments have reached the market, yet. Many of the intellectual properties have been sold off to keep the company alive. They are making progress with one treatment that has reached Phase III, though in a small study. Completion of the trial, as well as sufficient progress to justify applying for FDA approval is possibly years away. If they succeed, they will be famous, help society, and hopefully make the shareholders’ stocks rise. In the meantime, we wait.
DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results are made public - which would spark a spike that might price me out of the sale. Stay tuned.